Last reviewed 2026-04-23 · How we verify

LIV-GAMMA SN Inj.10%

SK Plasma Co., Ltd. · Phase 3 active Biologic

LIV-GAMMA SN Inj.10% is a Intravenous immunoglobulin (IVIG) Biologic drug developed by SK Plasma Co., Ltd.. It is currently in Phase 3 development for Primary immunodeficiency disorders, Immune thrombocytopenia (ITP), Chronic inflammatory demyelinating polyneuropathy (CIDP).

LIV-GAMMA SN is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by delivering pooled human antibodies to modulate immune responses.

LIV-GAMMA SN is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by delivering pooled human antibodies to modulate immune responses. Used for Primary immunodeficiency disorders, Immune thrombocytopenia (ITP), Chronic inflammatory demyelinating polyneuropathy (CIDP).

At a glance

Generic name	LIV-GAMMA SN Inj.10%
Sponsor	SK Plasma Co., Ltd.
Drug class	Intravenous immunoglobulin (IVIG)
Target	Fc receptors, complement system, pathogenic antigens
Modality	Biologic
Therapeutic area	Immunology, Hematology
Phase	Phase 3

Mechanism of action

This is a 10% intravenous immunoglobulin derived from human plasma that contains a broad spectrum of antibodies against various pathogens and antigens. It functions by providing immediate passive immunization, neutralizing pathogens, enhancing opsonization and complement activation, and modulating inflammatory immune responses through Fc receptor engagement and idiotypic interactions.

Approved indications

Primary immunodeficiency disorders
Immune thrombocytopenia (ITP)
Chronic inflammatory demyelinating polyneuropathy (CIDP)
Kawasaki disease

Common side effects

Headache
Fever
Chills
Myalgia
Infusion site reactions
Thrombosis
Aseptic meningitis

Key clinical trials

A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LIV-GAMMA SN Inj.10% CI brief — competitive landscape report
LIV-GAMMA SN Inj.10% updates RSS · CI watch RSS
SK Plasma Co., Ltd. portfolio CI

Frequently asked questions about LIV-GAMMA SN Inj.10%

What is LIV-GAMMA SN Inj.10%?

LIV-GAMMA SN Inj.10% is a Intravenous immunoglobulin (IVIG) drug developed by SK Plasma Co., Ltd., indicated for Primary immunodeficiency disorders, Immune thrombocytopenia (ITP), Chronic inflammatory demyelinating polyneuropathy (CIDP).

How does LIV-GAMMA SN Inj.10% work?

LIV-GAMMA SN is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by delivering pooled human antibodies to modulate immune responses.

What is LIV-GAMMA SN Inj.10% used for?

LIV-GAMMA SN Inj.10% is indicated for Primary immunodeficiency disorders, Immune thrombocytopenia (ITP), Chronic inflammatory demyelinating polyneuropathy (CIDP), Kawasaki disease.

Who makes LIV-GAMMA SN Inj.10%?

LIV-GAMMA SN Inj.10% is developed by SK Plasma Co., Ltd. (see full SK Plasma Co., Ltd. pipeline at /company/sk-plasma-co-ltd).

What drug class is LIV-GAMMA SN Inj.10% in?

LIV-GAMMA SN Inj.10% belongs to the Intravenous immunoglobulin (IVIG) class. See all Intravenous immunoglobulin (IVIG) drugs at /class/intravenous-immunoglobulin-ivig.

What development phase is LIV-GAMMA SN Inj.10% in?

LIV-GAMMA SN Inj.10% is in Phase 3.

What are the side effects of LIV-GAMMA SN Inj.10%?

Common side effects of LIV-GAMMA SN Inj.10% include Headache, Fever, Chills, Myalgia, Infusion site reactions, Thrombosis.

What does LIV-GAMMA SN Inj.10% target?

LIV-GAMMA SN Inj.10% targets Fc receptors, complement system, pathogenic antigens and is a Intravenous immunoglobulin (IVIG).

Drug class: All Intravenous immunoglobulin (IVIG) drugs
Target: All drugs targeting Fc receptors, complement system, pathogenic antigens
Manufacturer: SK Plasma Co., Ltd. — full pipeline
Therapeutic area: All drugs in Immunology, Hematology
Indication: Drugs for Primary immunodeficiency disorders
Indication: Drugs for Immune thrombocytopenia (ITP)
Indication: Drugs for Chronic inflammatory demyelinating polyneuropathy (CIDP)
Compare: LIV-GAMMA SN Inj.10% vs similar drugs
Pricing: LIV-GAMMA SN Inj.10% cost, discount & access